Topic
Biosimilars
856 published works
Big Molecule Watch
FDA Accepts Dr. Reddy’s Laboratories’ BLA for Abatacept Biosimilar
By Emma Murray
Dr. Reddy’s Laboratories (“Dr. Reddy’s”) announced on February 22 that the FDA accepted its BLA for DRL_AB, a proposed interchangeable biosimilar to Bristol-Myers Squibb’s ORENCIA® (abatacept) IV for infusion. According…
Big Molecule Watch
Janssen Files BPCIA Complaint Against Bio-Thera and Accord Related to Golimumab Biosimilar
By Christopher Cassella|Kevin DeJong
On March 3, Janssen Biotech, Inc. and Janssen Sciences Ireland UC (collectively, “Janssen”) filed a BPCIA complaint in the U.S. District Court for the District of Delaware against Accord BioPharma,…
Biosimilars Law Bulletin
ITC as a Biosimilar Battleground: Genentech Challenges Biocon’s Pertuzumab Biosimilar
By Sheena Wang, Jennifer P. Nock
On February 27, 2026, Genentech filed a complaint at the U.S. International Trade Commission (ITC) alleging that Biocon’s importation of its pertuzumab biosimilar, BMAB 1500/PERT-IJS (“BMAB 1500”), violates 19 U.S.C.…
Big Molecule Watch
Genentech Brings Pertuzumab Biosimilar Fight to the ITC
By Natasha Daughtrey|Kevin DeJong|Christopher Cassella
On February 27, 2026, Genentech filed a Section 337 complaint at the U.S. International Trade Commission (ITC) targeting Biocon’s proposed pertuzumab biosimilar, BMAB 1500/PERT-IJS, which references Genentech’s PERJETA®. The complaint,…
Big Molecule Watch
European Biosimilar Updates
On February 13, 2026, STADA and Bio-Thera announced that they have received European Marketing Authorization for GOTENFIA®, a golimumab biosimilar to Johnson & Johnson’s SIMPONI®. GOTENFIA® is a human monoclonal…
Big Molecule Watch
FDA Approves Accord’s FILKRI (filgrastim-laha), a Biosimilar to NEUPOGEN
By Yoko Bian
On February 17, 2026, the U.S. Food and Drug Administration (FDA) approved FILKRI (filgrastim-laha), a biosimilar to Amgen’s NEUPOGEN (filgrastim). FILKRI was developed by Accord BioPharma, the U.S. specialty division…
Big Molecule Watch
Formycon and Lotus Expand Collaboration in Asia-Pacific Region to Pembrolizumab Biosimilar
On February 11, 2026, Formycon AG and Lotus Pharmaceutical announced the execution of an exclusive license agreement directed to Formycon’s pembrolizumab biosimilar candidate, FYB206. Pembrolizumab is currently approved as KEYTRUDA…
Spicy IP
ER Squibb to map Zydus’s product: Does this mean closure?
There has been another development in ER Squibb v Zydus, at the center of which is Nivolumab, an anti-cancer drug. Readers will remember that on 12th January 2025, a division bench of…
Big Molecule Watch
Samsung and Regeneron Settle Aflibercept BPCIA Case
By Riley Wyberg
On February 11, 2026, Samsung Bioepis, Co., Ltd (“Samsung”) and Regeneron Pharmaceuticals, Inc. (“Regeneron”) filed a Joint Stipulation and Proposed Order seeking to dismiss all claims and counterclaims without prejudice…
Big Molecule Watch
Hikma Launches Denosumab Biosimilars ENOBY and XTRENBO
On January 19, 2026, Hikma announced the U.S. launch of ENOBY (denosumab-qbde) and XTRENBO (denosumab-qbde)—denosumab biosimilars referencing Amgen’s PROLIA and XGEVA, respectively. As recited in the announcement, “[d]enosumab is indicated for treating osteoporosis in…